CERo Non Current Assets Total vs Total Current Liabilities Analysis
| CEROW Stock | 0.01 0 14.29% |
CERo Therapeutics financial indicator trend analysis is way more than just evaluating CERo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CERo Therapeutics is a good investment. Please check the relationship between CERo Therapeutics Non Current Assets Total and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Non Current Assets Total vs Total Current Liabilities
Non Current Assets Total vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CERo Therapeutics Non Current Assets Total account and Total Current Liabilities. At this time, the significance of the direction appears to have pay attention.
The correlation between CERo Therapeutics' Non Current Assets Total and Total Current Liabilities is -0.71. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of CERo Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of CERo Therapeutics' Non Current Assets Total and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of CERo Therapeutics Holdings are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Non Current Assets Total i.e., CERo Therapeutics' Non Current Assets Total and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | -0.71 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on CERo Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of CERo Therapeutics Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from CERo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CERo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. Selling General Administrative is likely to drop to 2,748 in 2024. Enterprise Value Over EBITDA is likely to drop to -31.51 in 2024
| 2010 | 2022 | 2023 | 2024 (projected) | Interest Income | 986.7K | 142.1K | 127.9K | 121.5K | Net Interest Income | 986.7K | 142.1K | 127.9K | 121.5K |
CERo Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
CERo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.